Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alza Expects Doxil-Hycamtin Ovarian Cancer Study Results To Drive Sales

Executive Summary

Alza expects interim results from a Phase III trial comparing its liposomal doxorubicin product Doxil with SmithKline Beecham's Hycamtin (topotecan) in ovarian cancer will accelerate Doxil sales. The results will be presented at the American Society of Clinical Oncology meeting in New Orleans May 20.

You may also be interested in...



Oncologic Accelerated Approval Phase IV Studies For 7 Drugs To Be Reviewed

Accelerated approval Phase IV commitments for seven oncologic products will be reviewed at the March 12-13 meeting of FDA's Oncologic Drugs Advisory Committee

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

UsernamePublicRestriction

Register

OM013164

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel